As of 1 July 2022, Medicare rebates are available for patients suffering from prostate cancer.
Medicare will now cover the cost of whole-body prostate-specific membrane antigen (PSMA) PET-CT scans for initial staging of intermediate to high-risk patients with prostate cancer, as well as restaging for patients with recurrent prostate cancer.
Note: conditions apply as a certain criteria must be met.
More specific information regarding these Medicare changes is available from Medicare.
Envision is a leader in PET-CT, consistently delivering a comprehensive diagnostic and therapeutic service with a Gallium 68 generator on site.
Envision has built a reputation of being on par with Australia’s leading tertiary academic institutions in terms of referrer demand and case complexity.
To learn more about the Gallium 68 PSMA PET-CT performed at Envision, click here.